Lab technicians

Comparison of Free Light Chain assays in Myeloma and Non-Myeloma patients reveals insights into Myeloma biology and false-positive rates - Part 2

Advancing Healthcare Webinar Series

Naveen Bangia, Ph.D.
Siemens Healthineers


Join Siemens Healthineers as Dr. Naveen Bangia leads us through the scientific literature that provides a deeper understanding of free light chain biology in patients with, and without, Multiple Myeloma.

Speaking on these findings, Naveen Bangia, Ph.D. Siemens Healthineers, will help you:

  • Understand the differences in Free Light Chain assays that are available
  • Interpret differences in Free Light Chain test results between different methods
  • Explain the reasons for, and practical implications of, non-interchangeable assays
  • Understand the impact of different Free Light Chain assays on patients with renal impairment

If you missed part one, please visit our website to view an overview of the role of free light chains in diagnosing patients with multiple myeloma.


Naveen Bangia, Ph.D.
Siemens Healthineers

Dr. Bangia earned his PhD at the University of Toronto in Toronto, Canada. After postdoctoral work at Yale University, he started his career as a faculty member at Roswell Park Cancer Center and the University at Buffalo where he performed cancer research in the areas of HLA class I antigen presentation, protein folding, proteasome biology and Multiple Myeloma. Dr. Bangia has been working in scientific affairs in the area of Multiple Myeloma for the past 8 years. He is an expert in free light chain testing for diagnosis of monitoring of patients with monoclonal gammopathies such as Multiple Myeloma and AL Amyloidosis. He supports laboratories, clinicians and patients through presentations and collaborative studies.

Subscription Button Icon
Be the first to know about our events, training, and news